Placebo controlled study of rosiglitazone in HIV lipoatrophy.

Trial Profile

Placebo controlled study of rosiglitazone in HIV lipoatrophy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Atherosclerosis; Hyperlipidaemia
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2008 The expected completion date for this trial is now 1 Apr 2009 (source: ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top